ArticleAmerican journal of translational research2026
Correlation of serum MAp44 protein concentration with degree of myocardial injury and 30-day prognosis in patients with acute myocardial infarction.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the relationship between serum mannan-binding lectin-associated protein 44 (MAp44) level and myocardial injury severity in acute myocardial infarction (AMI) patients, and explore its value for 30-day prognostic assessment.
methodsA retrospective study included 128 AMI patients admitted to The First Hospital of Zhangjiakou from January 2023 to June 2024, divided into mild (n=57) and severe myocardial injury groups (n=71). General data and MAp44 levels were compared. For 30-day prognosis, patients were stratified into a major adverse cardiovascular event (MACE, n=37) and a non-MACE group (n=91). Univariate and multivariate analyses identified poor prognostic factors, and predictive values of indicators were compared. An independent cohort (82 AMI patients, February-October 2025) validated the model.
resultsThe severe group had significantly lower MAp44 and higher cardiac troponin T (cTnT) than the mild group (P<0.001). MAp44 was negatively correlated with cTnT (r=-0.666, P<0.001). The 30-day MACE incidence was 28.91%. Extensive infarction, ≥2 coronary lesions, elevated cTnT, and low MAp44 were MACE risk factors (P<0.05). The combined model (infarction size + coronary lesions + cTnT, and + MAp44) had the highest prognostic value (AUC=0.890, sensitivity =78.40%, specificity =83.50%), with 84.1% accuracy in the validation cohort.
conclusionSerum MAp44 levels decrease with increasing myocardial injury severity in AMI patients; low MAp44 is an independent risk factor for 30-day MACE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.